SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Yoriyuki Konno(National Institute of Infectious Diseases), Kei Sato(National Institute of Infectious Diseases)
Cell Reports
September 1, 2020
10.1016/j.celrep.2020.108185
Cited by 438

Related Papers

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
|Nature|2022|748
An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity
|bioRxiv (Cold Spring Harbor Laboratory)|2021|74
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75
|bioRxiv (Cold Spring Harbor Laboratory)|2022|44
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
|bioRxiv (Cold Spring Harbor Laboratory)|2023|24
Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant
|bioRxiv (Cold Spring Harbor Laboratory)|2023|20